Natalie M. Kistler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Natalie M. Kistler has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Nathanael D. Heckmann
Department of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, California
3 shared publications - Jay R. Lieberman
Department of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
2 shared publications - Mary K. Richardson
Department of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, California
2 shared publications - Aidan Lindgren
Keck School of Medicine of the University of Southern California
1 shared publication - Amiethab A. Aiyer
Department of Orthopaedic Surgery, The Johns Hopkins University, Baltimore, Maryland
1 shared publication - Amin Nakhostin-Ansari
Neuromusculoskeletal Research Center, Department of Physical Medicine and Rehabilitation, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- Open Access
- 17 September 2026
- Published by SAGE Publications in Global Spine Journal
Resurgence in BMP Use in Spine Surgery: An Analysis From 2010 to 2022
Study Design: Retrospective Cohort. Objectives: To evaluate trends in bone morphogenetic protein (BMP) utilization across spinal fusion procedures. Methods: Patients undergoing anterior cervical discectomy and fusion (ACDF), posterior cervical decompression and fusion (PCDF), anterior lumbar interbody fusion (ALIF), or posterior/transforaminal lumbar interbody fusion (PLIF/TLIF) between January 1, 2010 and April 30, 2023 were identified in the PearlDiver Mariner Database. BMP utilization was identified using ICD-9/10 codes and assessed annually as a percentage of total cases, with 2023 omitted due to incomplete data. Subgroup analysis stratified annual trends by number of levels fused. Temporal trends in patient demographics were compared between early (2010-2016) and late (2017-2023) cohorts using Welch’s t-test and Pearson chi-squared test of independence. Results: A total of 596,453 ACDF, 104,287 PCDF, 159,575 ALIF, and 622,252 PLIF/TLIF cases were identified, respectively. Across all procedures, BMP utilization declined to a nadir in 2017, followed by marked increase. From 2017 to 2022, BMP utilization increased by 667% in ACDF, 1138% in PCDF, 441% in ALIF, and 900% in PLIF/TLIF. BMP use was higher in multi-level PCDF and PLIF/TLIF compared to single-level, whereas ALIF demonstrated slightly higher utilization in single-level cases. In the later cohort, patients receiving BMP were older, had greater comorbidity burden, and longer hospital stays across all procedures (p<0.001). Conclusions: BMP utilization in spine surgery declined steadily until 2017, followed by marked increase through 2022, particularly in multi-level posterior cervical and lumbar fusions and among high-risk patients. This likely reflects evolving evidence supporting optimized dosing and improved safety profiles.
- 17 September 2026
- Published by SAGE Publications in Global Spine Journal
Open AccessResurgence in BMP Use in Spine Surgery: An Analysis From 2010 to 2022
Study Design: Retrospective Cohort. Objectives: To evaluate trends in bone morphogenetic protein (BMP) utilization across spinal fusion procedures. Methods: Patients undergoing anterior cervical discectomy and fusion (ACDF), posterior cervical decompression and fusion (PCDF), anterior lumbar interbody fusion (ALIF), or posterior/transforaminal lumbar interbody fusion (PLIF/TLIF) between January 1, 2010 and April 30, 2023 were identified in the PearlDiver Mariner Database. BMP utilization was identified using ICD-9/10 codes and assessed annually as a percentage of total cases, with 2023 omitted due to incomplete data. Subgroup analysis stratified annual trends by number of levels fused. Temporal trends in patient demographics were compared between early (2010-2016) and late (2017-2023) cohorts using Welch’s t-test and Pearson chi-squared test of independence. Results: A total of 596,453 ACDF, 104,287 PCDF, 159,575 ALIF, and 622,252 PLIF/TLIF cases were identified, respectively. Across all procedures, BMP utilization declined to a nadir in 2017, followed by marked increase. From 2017 to 2022, BMP utilization increased by 667% in ACDF, 1138% in PCDF, 441% in ALIF, and 900% in PLIF/TLIF. BMP use was higher in multi-level PCDF and PLIF/TLIF compared to single-level, whereas ALIF demonstrated slightly higher utilization in single-level cases. In the later cohort, patients receiving BMP were older, had greater comorbidity burden, and longer hospital stays across all procedures (p<0.001). Conclusions: BMP utilization in spine surgery declined steadily until 2017, followed by marked increase through 2022, particularly in multi-level posterior cervical and lumbar fusions and among high-risk patients. This likely reflects evolving evidence supporting optimized dosing and improved safety profiles.
- 18 June 2025
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology
- Vol. 195, 112440
Effect of otolaryngology analgesia guidelines on opioid prescribing in pediatric tonsillectomy
- 18 June 2025
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology
- Vol. 195, 112440
Effect of otolaryngology analgesia guidelines on opioid prescribing in pediatric tonsillectomy
- 22 January 2024
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 106 (5) , 414-424
Increasing Burden of Lower-Extremity Fractures in the Middle East and North Africa (MENA)
Background: Lower-extremity fractures (LEFs) account for >30% of all skeletal injuries, contributing to the global health and economic burden. Fracture epidemiology in the Middle East and North Africa (MENA) region has been studied little. Health factors and disease epidemiology differ greatly among populations in MENA despite cultural, political, and economic similarities among the region’s countries. This study examined the epidemiology of LEFs and the need for rehabilitation in MENA from 1990 to 2019. Methods: We examined the epidemiology of fractures of the pelvis, hip, femur, patella, tibia, fibula, ankle, and foot bones using Global Burden of Disease (GBD) data. Fracture incidence, counts, and rates were measured for males and females across age groups in the 21 MENA countries as identified by the GBD data set. Associations between years of healthy life lost due to disability (YLD) resulting from fracture and the Socio-demographic Index (SDI) were analyzed. Results: In contrast to the global trend, the age-standardized incidence rate (ASIR) of LEFs in the MENA region increased by 4.57% from 1990 to 2019. In 2019, the highest ASIR among fractures was attributed to fractures of the patella, fibula, tibia, or ankle (434.36 per 100,000), most frequently occurring among those 20 to 24 years of age. In 2019, the highest ASIR of all fractures was noted in Saudi Arabia (2,010.56 per 100,000) and the lowest, in Sudan (523.29 per 100,000). The greatest increases from 1990 to 2019 in the ASIR of LEFs were noted in Yemen (132.39%), Syria (107.27%), and Afghanistan (94.47%), while the largest decreases were found in Kuwait (−62.72%), Sudan (−48.72%), and Iran (−45.37%). In 2019, the YLD rate of LEFs had increased to 277.65 per 100,000, up from 235.55 per 100,000 in 1990. Conclusions: Between 1990 and 2019, LEFs increased in the MENA region. Violence, war, and road traffic accidents increased, leading to a high rate of fractures, especially among youth. Low bone-mineral density related to vitamin D deficiency has also been reported as a risk factor for fracture in the region. Regional health authorities should be informed of fracture patterns by this study. Level of Evidence: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.
- 22 January 2024
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 106 (5) , 414-424
Increasing Burden of Lower-Extremity Fractures in the Middle East and North Africa (MENA)
Background: Lower-extremity fractures (LEFs) account for >30% of all skeletal injuries, contributing to the global health and economic burden. Fracture epidemiology in the Middle East and North Africa (MENA) region has been studied little. Health factors and disease epidemiology differ greatly among populations in MENA despite cultural, political, and economic similarities among the region’s countries. This study examined the epidemiology of LEFs and the need for rehabilitation in MENA from 1990 to 2019. Methods: We examined the epidemiology of fractures of the pelvis, hip, femur, patella, tibia, fibula, ankle, and foot bones using Global Burden of Disease (GBD) data. Fracture incidence, counts, and rates were measured for males and females across age groups in the 21 MENA countries as identified by the GBD data set. Associations between years of healthy life lost due to disability (YLD) resulting from fracture and the Socio-demographic Index (SDI) were analyzed. Results: In contrast to the global trend, the age-standardized incidence rate (ASIR) of LEFs in the MENA region increased by 4.57% from 1990 to 2019. In 2019, the highest ASIR among fractures was attributed to fractures of the patella, fibula, tibia, or ankle (434.36 per 100,000), most frequently occurring among those 20 to 24 years of age. In 2019, the highest ASIR of all fractures was noted in Saudi Arabia (2,010.56 per 100,000) and the lowest, in Sudan (523.29 per 100,000). The greatest increases from 1990 to 2019 in the ASIR of LEFs were noted in Yemen (132.39%), Syria (107.27%), and Afghanistan (94.47%), while the largest decreases were found in Kuwait (−62.72%), Sudan (−48.72%), and Iran (−45.37%). In 2019, the YLD rate of LEFs had increased to 277.65 per 100,000, up from 235.55 per 100,000 in 1990. Conclusions: Between 1990 and 2019, LEFs increased in the MENA region. Violence, war, and road traffic accidents increased, leading to a high rate of fractures, especially among youth. Low bone-mineral density related to vitamin D deficiency has also been reported as a risk factor for fracture in the region. Regional health authorities should be informed of fracture patterns by this study. Level of Evidence: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.
- 21 December 2023
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 106 (4) , 276-287
Higher Blood Glucose Levels on the Day of Surgery Are Associated with an Increased Risk of Periprosthetic Joint Infection After Total Hip Arthroplasty
Background: Hyperglycemia has been identified as a risk factor for periprosthetic joint infection (PJI) after total hip arthroplasty (THA). However, there is no consensus with regard to the preoperative blood glucose level (BGL) on the day of the surgical procedure associated with increased risk. We sought to identify preoperative BGL thresholds associated with an increased risk of PJI. Methods: The Premier Healthcare Database was retrospectively queried for adult patients who underwent primary, elective THA and had a measurement of the preoperative BGL recorded on the day of the surgical procedure (preoperative BGL) from January 1, 2016, to December 31, 2021. The association between preoperative BGL and 90-day PJI risk was modeled using multivariable logistic regression with restricted cubic splines. Patients with and without diabetes with a preoperative BGL associated with 1.5 times greater odds of PJI (high preoperative BGL) were then compared with patients with a normal preoperative BGL. Results: In this study, 90,830 patients who underwent THA and had a recorded preoperative BGL were identified. The preoperative BGL associated with 1.5 times greater odds of PJI was found to be 277 mg/dL in patients with diabetes and 193 mg/dL in patients without diabetes. Compared with the normal preoperative BGL cohort, those with high preoperative BGL had increased odds of PJI (adjusted odds ratio [OR], 2.60 [95% confidence interval (CI), 1.45 to 4.67] for patients with diabetes and 1.66 [95% CI, 1.10 to 2.51] for patients without diabetes) and 90-day readmissions (adjusted OR, 1.92 [95% CI, 1.45 to 2.53] for patients with diabetes and 1.66 [95% CI, 1.37 to 2.00] for patients without diabetes). Conclusions: Increased preoperative BGL was found to be associated with an increased risk of PJI following primary THA. Surgeons should be aware of patients with diabetes and a preoperative BGL of >277 mg/dL and patients without diabetes but with a preoperative BGL of >193 mg/dL. Level of Evidence: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.
- 21 December 2023
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 106 (4) , 276-287
Higher Blood Glucose Levels on the Day of Surgery Are Associated with an Increased Risk of Periprosthetic Joint Infection After Total Hip Arthroplasty
Background: Hyperglycemia has been identified as a risk factor for periprosthetic joint infection (PJI) after total hip arthroplasty (THA). However, there is no consensus with regard to the preoperative blood glucose level (BGL) on the day of the surgical procedure associated with increased risk. We sought to identify preoperative BGL thresholds associated with an increased risk of PJI. Methods: The Premier Healthcare Database was retrospectively queried for adult patients who underwent primary, elective THA and had a measurement of the preoperative BGL recorded on the day of the surgical procedure (preoperative BGL) from January 1, 2016, to December 31, 2021. The association between preoperative BGL and 90-day PJI risk was modeled using multivariable logistic regression with restricted cubic splines. Patients with and without diabetes with a preoperative BGL associated with 1.5 times greater odds of PJI (high preoperative BGL) were then compared with patients with a normal preoperative BGL. Results: In this study, 90,830 patients who underwent THA and had a recorded preoperative BGL were identified. The preoperative BGL associated with 1.5 times greater odds of PJI was found to be 277 mg/dL in patients with diabetes and 193 mg/dL in patients without diabetes. Compared with the normal preoperative BGL cohort, those with high preoperative BGL had increased odds of PJI (adjusted odds ratio [OR], 2.60 [95% confidence interval (CI), 1.45 to 4.67] for patients with diabetes and 1.66 [95% CI, 1.10 to 2.51] for patients without diabetes) and 90-day readmissions (adjusted OR, 1.92 [95% CI, 1.45 to 2.53] for patients with diabetes and 1.66 [95% CI, 1.37 to 2.00] for patients without diabetes). Conclusions: Increased preoperative BGL was found to be associated with an increased risk of PJI following primary THA. Surgeons should be aware of patients with diabetes and a preoperative BGL of >277 mg/dL and patients without diabetes but with a preoperative BGL of >193 mg/dL. Level of Evidence: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.
- 15 November 2023
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 106 (1) , 30-38
Tranexamic Acid Is Safe in Patients with a History of Venous Thromboembolism Undergoing Total Joint Arthroplasty
Background: Tranexamic acid (TXA) is increasingly utilized during total knee arthroplasty (TKA) and total hip arthroplasty (THA) to decrease blood loss; however, there are concerns with regard to potential thromboembolic complications, particularly in high-risk patients. This study sought to define a subset of patients at elevated risk for thromboembolic complications following total joint arthroplasty (TJA) and to compare postoperative outcomes between patients who received TXA and those who did not. Methods: Patients who underwent primary, elective TJA from 2015 to 2021 were identified in the Premier Healthcare Database. Patients with a history of venous thromboembolism, defined as a history of pulmonary embolism or deep vein thrombosis, were identified and formed the high-risk cohort. Patient demographic characteristics, hospital factors, patient comorbidities, antithrombotic medication use, perioperative blood transfusion, and 90-day complications were assessed and compared between patients who received TXA and those who did not. Univariate regression and multivariable regression were performed to account for potential confounders. Results: The high-risk cohort comprised 70,759 patients who underwent TJA, of whom 46,074 (65.1%) received TXA and 24,685 (34.9%) did not. After controlling for confounding factors, patients in the TXA cohort had similar risks of pulmonary embolism (adjusted odds ratio [OR], 0.90 [95% confidence interval (CI), 0.79 to 1.02]; p = 0.097), stroke (adjusted OR, 0.97 [95% CI, 0.69 to 1.37]; p = 0.867), and myocardial infarction (adjusted OR, 0.93 [95% CI, 0.69 to 1.24]; p = 0.614) compared with patients who did not receive TXA. Patients who received TXA demonstrated decreased risks of transfusion (adjusted OR, 0.42 [95% CI, 0.38 to 0.46]; p < 0.001) and 90-day readmission (adjusted OR, 0.87 [95% CI, 0.80 to 0.94]; p < 0.001). Conclusions: TXA utilization was not associated with an increased risk of postoperative pulmonary embolism, stroke, or myocardial infarction in patients with a history of venous thromboembolism. Furthermore, patients who received TXA had a decreased risk of transfusion and readmission. This evidence suggests that TXA may be safely utilized among select high-risk patients. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
- 15 November 2023
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 106 (1) , 30-38
Tranexamic Acid Is Safe in Patients with a History of Venous Thromboembolism Undergoing Total Joint Arthroplasty
Background: Tranexamic acid (TXA) is increasingly utilized during total knee arthroplasty (TKA) and total hip arthroplasty (THA) to decrease blood loss; however, there are concerns with regard to potential thromboembolic complications, particularly in high-risk patients. This study sought to define a subset of patients at elevated risk for thromboembolic complications following total joint arthroplasty (TJA) and to compare postoperative outcomes between patients who received TXA and those who did not. Methods: Patients who underwent primary, elective TJA from 2015 to 2021 were identified in the Premier Healthcare Database. Patients with a history of venous thromboembolism, defined as a history of pulmonary embolism or deep vein thrombosis, were identified and formed the high-risk cohort. Patient demographic characteristics, hospital factors, patient comorbidities, antithrombotic medication use, perioperative blood transfusion, and 90-day complications were assessed and compared between patients who received TXA and those who did not. Univariate regression and multivariable regression were performed to account for potential confounders. Results: The high-risk cohort comprised 70,759 patients who underwent TJA, of whom 46,074 (65.1%) received TXA and 24,685 (34.9%) did not. After controlling for confounding factors, patients in the TXA cohort had similar risks of pulmonary embolism (adjusted odds ratio [OR], 0.90 [95% confidence interval (CI), 0.79 to 1.02]; p = 0.097), stroke (adjusted OR, 0.97 [95% CI, 0.69 to 1.37]; p = 0.867), and myocardial infarction (adjusted OR, 0.93 [95% CI, 0.69 to 1.24]; p = 0.614) compared with patients who did not receive TXA. Patients who received TXA demonstrated decreased risks of transfusion (adjusted OR, 0.42 [95% CI, 0.38 to 0.46]; p < 0.001) and 90-day readmission (adjusted OR, 0.87 [95% CI, 0.80 to 0.94]; p < 0.001). Conclusions: TXA utilization was not associated with an increased risk of postoperative pulmonary embolism, stroke, or myocardial infarction in patients with a history of venous thromboembolism. Furthermore, patients who received TXA had a decreased risk of transfusion and readmission. This evidence suggests that TXA may be safely utilized among select high-risk patients. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.